If approved, the less burdensome version of Leqembi could be used to treat patients at home or in medical facilities, help Eisai and Biogen differentiate Leqembi from Eli Lilly's recently approved ...

Did Eli Lilly just say checkmate to Novo Nordisk? Well, an approval for an oral drug would represent a big victory. First, its likely many people would prefer a daily pill instead of an injection ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock ... and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development ...

Eli Lilly (NYSE: LLY) has been growing its sales ... Zepbound is administered via subcutaneous injection once a week. However, some patients don't like to poke needles into their skin and would ...

when the FDA issued a new decision determining the tirzepatide injection shortage had been resolved following two years of shortages. However, Eli Lilly claims those products were not comparable ...

Shares in Eli Lilly rose sharply ... Nordisk's Wegovy (semaglutide) and Lilly's dual GIP/GLP-1 agonist Zepbound (tirzepatide) – which are given by weekly injection. The encouraging orforglipron ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Novo Nordisk and Eli Lilly currently dominate the weight-loss market, but their drugs are administered by injection. Both are working on pill versions that are seen as more convenient for patients ...

Eli Lilly's next-generation products look promising ... Ozempic, Wegovy, Mounjaro, and Zepound are all administered via injection, but the next wave of GLP-1 agonists is in development, including ...